about
Human recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisKukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment.A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo.Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging drugs in sepsis.
@en
Emerging drugs in sepsis.
@nl
type
label
Emerging drugs in sepsis.
@en
Emerging drugs in sepsis.
@nl
prefLabel
Emerging drugs in sepsis.
@en
Emerging drugs in sepsis.
@nl
P2093
P2860
P1476
Emerging drugs in sepsis
@en
P2093
Claude Martin
Fabrice Michel
Marc Leone
Sandrine Wiramus
P2860
P356
10.1517/14728210903559860
P407
P577
2010-03-01T00:00:00Z